CALB2 is a Mechanoresistance Gene in Metastatic Prostate Cancer
Advanced Science · 2026
DOI: 10.1002/advs.76535 ↗At a glance
Journal article in Advanced Science, 2026. Written by Abigail R Fabiano and 10 co-authors. Institution: Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee, USA. Major MEDLINE topics: Prostatic Neoplasms, Neoplastic Cells, Circulating. Cited 1 times so far (Crossref); 96 references. The full text is freely available (open access, CC BY 4.0). Funded by: NCI NIH HHS, Genetic Design and Engineering Center (GDEC) at Rice University, Vanderbilt Digestive Disease Research Center.
Abstract (original language)
It remains unclear how circulating tumor cells (CTCs) adapt to and survive mechanical forces in the bloodstream, including fluid shear stress (FSS), making it critical to define the mechanisms that enable their survival and promote metastasis. To model these forces, we generated “mechanoresistant” (MR) LNCaP and PC3 prostate cancer (PCa) cell lines by repeatedly exposing cells to high‑intensity (HI) FSS (3950 dyn/cm 2 ). LNCaP MR cells acquired marked resistance to HI FSS, exhibiting significantly reduced apoptosis, while PC3 cells demonstrated innate resistance. Bulk RNA‑sequencing revealed that LNCaP and PC3 MR cells developed distinct molecular programs. CALB2 (calretinin) emerged as a mechanoresistance gene selectively upregulated in PC3 MR cells, and CALB2 knockout significantly reduced viability upon re‑exposure to HI FSS. Analysis of CALB2 ‑high PCa cases captured patient‑level molecular heterogeneity, suggesting a mechanoadaptive state rather than a uniform aggressiveness‐driven tumor phenotype. This was consistent with the absence of correlation between CALB2 levels and Gleason Scores. In an orthotopic PCa mouse model, the PC3 MR condition displayed the most aggressive early tumor growth and the largest endpoint tumor volumes, consistent with enhanced proliferation. Together, these findings demonstrate that PCa cells acquire discrete mechanoadaptive phenotypes under extreme FSS, revealing targetable pathways to limit metastatic competence.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee, USA.
- Department of Bioengineering, Rice University, Houston, Texas, USA.
ORCID profiles: Michael R King
Funding
- NCI NIH HHS
- Genetic Design and Engineering Center (GDEC) at Rice University
- Vanderbilt Digestive Disease Research Center
- Cancer Prevention and Research Institute of Texas
- United States National Institute of Health
- NIDDK NIH HHS
- National Science Foundation Graduate Research Fellowship
- Vanderbilt Flow Cytometry Shared Resource is supported by the Vanderbilt Ingram Cancer Center
Cite
APA
Fabiano, A. R., Luo, A. C., Taufalele, P., Dombroski, J. A., Aalaei, E., Rowland, S. J., Cantú, M. S., Carter, A. T., Knoblauch, S. V., Reinhart-King, C. A., & King, M. R. (2026). CALB2 is a Mechanoresistance Gene in Metastatic Prostate Cancer. Advanced Science. https://doi.org/10.1002/advs.76535
Vancouver
Fabiano AR, Luo AC, Taufalele P, Dombroski JA, Aalaei E, Rowland SJ, et al. CALB2 is a Mechanoresistance Gene in Metastatic Prostate Cancer. Advanced Science. 2026. doi:10.1002/advs.76535
BibTeX
@article{Fabiano2026,
author = {Fabiano, Abigail R and Luo, Allen C and Taufalele, Paul and Dombroski, Jenna A and Aalaei, Ehsan and Rowland, Schyler J and Cantú, Melissa S and Carter, Alexandria T and Knoblauch, Samantha V and Reinhart-King, Cynthia A and King, Michael R},
title = {CALB2 is a Mechanoresistance Gene in Metastatic Prostate Cancer},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.76535}
}
EUVIMED